Evaluation of efficacy of Topical Timolol for treatment in conjunctival Pyogenic Granulom

Evaluation of efficacy of Topical Timolol for treatment in conjunctival Pyogenic Granuloma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160523028008N27

Enrollment

Registered

2023-01-13

Start date

2023-01-25

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyogenic granuloma. Pyogenic granuloma

Interventions

Intervention group: 46 patients with pyogenic granuloma of the eye conjunctiva will be treated with 5% topical timolol drops made by Sina Daro pharmaceutical company(Iran) twice a day for 3 to 6 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pyogenic granuloma Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Presence of previous similar lesions Lost of follow-up after 6 week.

Design outcomes

Primary

Measure	Time frame
Lesion healing. Timepoint: 6 weeks after treatment. Method of measurement: Eye examination.;Recurrence of the lesion. Timepoint: 6 weeks after treatment. Method of measurement: Eye examination.	—

Secondary

Measure	Time frame
Complication. Timepoint: 12 weeks after treatment. Method of measurement: Eye examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Eslami

Hamedan University of Medical Sciences

hrgb2005@yahoo.com+98 81 1828 5015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026